<DOC>
	<DOCNO>NCT02251275</DOCNO>
	<brief_summary>The purpose study evaluate describe long term safety tolvaptan patient autosomal dominant polycystic kidney disease ( ADPKD</brief_summary>
	<brief_title>Open-label Trial Evaluate Long Term Safety Titrated Immediate-release Tolvaptan Subjects With Autosomal Dominant Polycystic Kidney Disease</brief_title>
	<detailed_description>This trial phase 3b evaluate describe long-term safety tolvaptan treatment ADPKD patient CKD ( chronic kidney disease ) . Eligible Subjects enter trial Trial 156-08-271 Tolvaptan interventional trial . Renal function assess screen use historical laboratory value serum creatinine level calculate estimate glomerular filtration rate ( eGFR ) . General safety endpoint assess also relevant safety endpoint trial Serum transaminase elevation frequency &amp; Serum sodium excursion .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Male female subject ≥ 18 year confirm diagnosis ADPKD ( participation prior tolvaptan trial ) Completed transferred doubleblind Trial 15613210 ( 12month period include post treatment followup , regardless whether ontreatment offtreatment ) , Completed Trial 15608271 prior tolvaptan trial , Interrupted discontinue treatment prior tolvaptan ADPKD trial Trial 15613210 . Subjects may enrol medical monitor approval , additional close monitoring may require begin study 2 . Estimated glomerular filtration rate ( eGFR ) ≥ 20 mL/min/1.73m2 within 45 day baseline visit . Subjects eGFR 15 19 mL/min/1.73m2 may enrol medical monitor approval 3 . Diagnosis ADPKD modify PeiRavine criterion Need chronic diuretic use Hepatic impairment base liver function assessment expect ADPKD cystic liver disease Women childbearing potential ( WOCBP ) agree practice 2 different method birth control remain abstinent trial 30 day last dose IMP Women breastfeed and/or positive pregnancy test result prior receive IMP . Subjects contraindication require trial assessment ( contraindication optional assessment , eg , MRI limitation ) . Subjects opinion Investigator Medical Monitor , medical history medical finding inconsistent safety trial compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
</DOC>